Sera were tested for anti-HLA antibodies using the multiplex technology SPA. Class I (i.e. HLA-A/B) and class II (i.e. HLA-DR/DP/DQ) HLA antibodies were tested using reagents from One Lambda, Inc., Canoga Park CA, (LabScreen LS1A01 Lot 007 and LS2A01 Lot 004, commercialized in Switzerland by Ingen). Briefly, 20 μl of serum samples were incubated with HLA class I and HLA class II coated microspheres respectively for 30 min at dark and under gently agitation. The specimens were then washed 5 times before being incubated with anti-human IgG-conjugated phyco-erythrine in the same conditions as in the first incubation. The Labscan 100 flow analyzer (Luminex, Austin, TX) was used for beads and data acquisition. Data were then exported to the HLA Visual software (One Lambda) for analysis. The cut off level was define as a baseline normalized > 500 MFI. Presence of DSA was assigned by comparing the several HLA-specificities proposed by the software analysis with the HLA typing of the donor for all transplanted patients. The Luminex results did not influence transplant management (retrospective study).
. All transplanted patients had current and peak negative Tcell and B-cell CDC-crossmatch. No prospective flowcytometric or Luminex crossmatches were performed. All retrospective data were obtained by carefully reviewing the patient case-history.
RESULTS :
All sera were stocked at -80 °C and thawed just before analyses were performed. Table 1 .
All
• Pre-sensitizing events (prior transplants, pregnancies and female gender) were significantly more common in the group of patients with DSA than in the group without DSA (Table 1) .
• Approximately half of our patient population (55/113, 48,7%) had pre-transplant circulating anti-HLA antibodies. ( fig.1) • 11 of 113 patients (9.7 %) had pre-transplant DSA ( fig.1) • Out of a total of 11 AR episodes post-transplant, 6 had no anti-HLA antibodies and 5 were anti-HLA positive , but only 2 had pre-transplant DSA, of whom one developed AHR (C4d positive) at day 7 post-transplantation ( fig. 1) • 9 from 11 recipients had pre-transplant DSA and did not present any posttransplant rejections episodes. (Table 2) • There are no differencies between patients with only class I or only class II pretransplant DSA compared to patients with both or more in predicting outcome (Table 3) • Pre-transplant mean DSA-MFI values of the two kidney transplant recipients with acute rejection were at 1557 ± 954 (patient 1: anti-DR11 (1004), and patient 2: anti-A26 (1008) and anti-A11 (2659)). On the other hand, the pretransplant DSA-MFI values of the 9 kidney transplant recipients without any rejection episodes ranged from 694 up to 5717 (mean: 2758 ± 1938) ( fig.2) 
